Citation:Stintzing, S Jung, A Rossius, L Modest, DP von Weikersthal, LF Decker, T Kiani, A Al-Batran, S-E Vehling-Kaiser, U Heintges, T Moehler, M Scheithauer, W Kirchner, T Heinemann, V 2014

Citation

Stintzing, S Jung, A Rossius, L Modest, DP von Weikersthal, LF Decker, T Kiani, A Al-Batran, S-E Vehling-Kaiser, U Heintges, T Moehler, M Scheithauer, W Kirchner, T Heinemann, V. Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. J Clin Oncol 2014;32, abstract 445 Available from: http://meetinglibrary.asco.org/content/123133-143.

Critical appraisals

• Assign a critical appraisal

Cited by

1. Molecular pathology and biomarkers – implications for systemic therapy